Posts Tagged Pharma Financings

Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on Catabasis Pharmaceuticals, Inc.

by

Follow the Money to Bio/Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Catabasis Pharmaceuticals is a U.S. public bio/pharmaceutical company that focuses on the discovery and development of drugs to treat inflammatory and metabolic conditions. It has […]

Learn more

Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on OncoMed Pharmaceuticals, Inc.

by

Follow the Money to Bio/Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. OncoMed Pharmaceuticals is a U.S. public bio/pharmaceutical company that discovers and develops mAbs and small molecules for the treatment of cancer. It has raised $59.2 […]

Learn more

Follow the Money to Bio/Pharmaceutical Opportunities
Spotlight on Galena Biopharma, Inc.

by

Follow the Money to Bio/Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Galena Biopharma is a U.S. public bio/pharmaceutical company that develops targeted oncology treatments to address unmet medical needs that advance cancer care. It has raised […]

Learn more

Follow the Money to Pharmaceutical Opportunities
Spotlight on Medgenics, Inc.

by

Follow the Money to Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Medgenics is a U.S. public biopharmaceutical company that develops genomic medicine for the treatment of rare and difficult-to-treat chronic diseases such as anemia, hepatitis and […]

Learn more

Territory Watch:
Look Beyond the Usual to Capture New Business

by

The majority of bio/pharma funding events in the U.S. during 2014 and 2015 occurred outside the high-profile hubs of the San Francisco Bay Area and Boston. However, contract research organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) looking to capture new business will find substantial opportunities in geographically concentrated areas far beyond those more […]

Learn more

Follow the Money to Pharmaceutical Opportunities
Spotlight on Ignyta, Inc.

by

Follow the Money to Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Ignyta, Inc. is a U.S. public biopharmaceutical company that develops personalized medicine tests to improve the diagnosis and treatment of patients with autoimmune diseases such […]

Learn more

Follow the Money to Pharmaceutical Opportunities
Spotlight on Aradigm Corporation

by

Follow the Money to Pharmaceutical Opportunities highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Aradigm Corporation is a U.S. public biopharmaceutical company that develops and commercializes drugs delivered by inhalation for the treatment of severe respiratory disease. It plans […]

Learn more

Follow the Money: ArQule, Inc.

by

Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. ArQule, Inc. is a U.S. public biopharmaceutical company that develops innovative therapeutics for the treatment of cancer and rare diseases. They plan to raise $15.6 million in a […]

Learn more

Follow the Money: Amarantus Bioscience Holdings, Inc.

by

Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Amarantus Bioscience Holdings, Inc. is a U.S. public biopharmaceutical company that focuses on the discovery and early development of therapeutic proteins and diagnostic tests. As reported in the […]

Learn more

Follow the Money: Acceleron Pharma, Inc.

by

Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Acceleron Pharma is a U.S. public biopharmaceutical company that discovers and develops protein therapies for the treatment of musculoskeletal, metabolic and cancer-related diseases. As reported in the January […]

Learn more